---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-101126"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2026-03-11T23:59:59+00:00"
generated_at: "2026-05-15T14:50:44.082262+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Verrica Q4 2025: YCANTH net revenue up 130% to $15.3M; total revenue $35.6M

## Summary
- Q4 product revenue $3.7M vs $0.3M YoY; total revenue $35.6M in 2025, up from $7.6M in 2024.
- YCANTH dispensed units up 99% to 51,296 in 2025; SG&A cut by over 40% to $35.2M.
- Net loss $17.9M ($1.68/share) for full year 2025 vs $76.6M ($14.78/share) in 2024.
- Company has no outstanding debt; cash runway extended into Q1 2027.
- Phase 3 for common warts initiated; VP-315 advancing to Phase 3 for basal cell carcinoma.

## SEC filing metadata
- accession: 0001193125-26-101126
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2026-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/0001193125-26-101126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-101126
- JSON: https://secwatch.observer/filing/0001193125-26-101126.json
- Plain text: https://secwatch.observer/filing/0001193125-26-101126.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported Fourth Quarter and Full Year 2025 results: revenue $35.6 million.
  - Period: Fourth Quarter and Full Year 2025
  - Revenue: $35.6 million
  - Result: reported results
  source text: Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results – YCANTH ® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/0001193125-26-101126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.